Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank71
Studio
Year-over-Year Change

Price-to-earnings ratio

Percentile
P71
Within normal range
vs 2Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive growthElevated
PeriodValueYoY Change
202529.38+106.0%
2024-486.05-2151.9%
202323.69+170.1%
2022-33.78-175.1%
202144.96+108.3%
2020-539.23-17229.7%
20193.15-86.2%
201822.77-90.1%
2017229.37+117.7%
2016-1293.79-